医療レポート：Hepatitis C Virus-疫学予測（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 7
3 Epidemiology 8
3.1 Risk Factors and Comorbidities 8
3.1.1 The risk of contracting HCV is almost 50 times higher among injection drug users 9
3.1.2 There is a 10.9-fold increased risk of developing HCV infection through a blood transfusion 10
3.1.3 No current preventative therapy to reduce perinatal transmission 10
3.1.4 Metabolic syndrome is a common comorbidity in HCV-infected individuals 10
3.1.5 Chronic alcoholism greatly magnifies the risk of HCC 11
3.1.6 Hepatitis B virus and HCV share similar modes of transmission, resulting in co-infections 12
3.1.7 HCV/HIV co-infection complicates treatment options and accelerates liver damage 12
3.2 Global Trends 13
3.2.1 US 13
3.2.2 5EU 14
3.2.3 Japan 17
3.2.4 Brazil 18
3.2.5 China 18
3.3 Forecast Methodology 19
3.3.1 Sources Used 20
3.3.2 Forecast Assumptions and Methods 23
3.3.3 Forecast Assumptions and Methods (HCV Genotypes) 26
3.3.4 Sources Not Used 30
3.4 Epidemiology Forecast (2012–2022) 31
3.4.1 Total Prevalent Cases of HCV 31
3.4.2 Age-Specific Prevalent Cases of HCV 34
3.4.3 Sex-Specific Prevalent Cases of HCV 37
3.4.4 Age-Standardized Prevalence of HCV 38
3.4.5 HCV Genotype Class Distributions 40
3.5 Discussion 41
3.5.1 Conclusion on Epidemiology Trends 41
3.5.2 Limitations of the Analysis 42
3.5.3 Strengths of the Analysis 42
4 Appendix 43
4.1 Bibliography 43
4.2 About the Authors 54
4.2.1 Epidemiologists 54
4.2.2 Reviewers 54
4.2.3 Global Director of Epidemiology and Clinical Trials Analysis 55
4.2.4 Global Head of Healthcare 56
4.3 About GlobalData 57
4.4 About EpiCast 57
4.5 Contact Us 58
4.6 Disclaimer 58